Try our Advanced Search for more refined results

August 19, 2013

In re: Eisai Inc.

Track this case

Case Number:

13-1243

Court:

Appellate - DC Circuit

Nature of Suit:

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. October 25, 2013

    DC Circ. Rejects Esai's Petition Over Seizure Med Delay

    The D.C. Circuit on Tuesday shot down a bid from a U.S. unit of Japan's Eisai Co. Ltd. to force the U.S. Drug Enforcement Administration to speed up the process for scheduling its epilepsy drug Fycompa as a controlled substance, saying the company had not shown the need for such drastic action.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!